Navigation Links
Niaid / Barda Awards Elusys a $12 Million Contract to Further Develop Anthim, the Company's Anthrax Therapeutic
Date:9/25/2007

PINE BROOK, N.J., Sept. 25 /PRNewswire/ -- Elusys Therapeutics, Inc. (Elusys), a privately held biopharmaceutical company developing antibody-based therapies for the treatment of life-threatening infectious diseases, today announced it has been awarded a contract for $12 million for advanced development of Anthim(TM), the company's late-stage anthrax therapeutic. This project has been funded in whole or in part with Federal funds from the National Institute of Allergy and Infectious Disease, National Institutes of Health and the Biomedical Advanced Research and Development Authority, Department of Health and Human Services, under Contract No. HHSN272200700035C. To date, Elusys has received more than $32 million from NIAID/BARDA and the Department of Defense in support of Anthim and the company's Heteropolymer Antibody(TM) technology.

Elizabeth Posillico, Ph.D., President and Chief Executive Officer of Elusys, commented on the award, "Elusys is encouraged by the continued support from the U.S. Government and we look forward to extending our collaboration with NIAID/BARDA. We are confident that Elusys has developed a highly effective and valuable anthrax therapeutic for procurement under Project BioShield for addition to the U.S. Government's Strategic National Stockpile."

Dr. Posillico continued, "Inhalation of anthrax spores rapidly leads to death if patients are not treated immediately with specific antibiotics. Typically, victims of inhalation anthrax experience only vague symptoms until it is too late, when they are in toxemia, leaving antibiotics largely ineffective. Anthrax vaccines are also ineffective unless victims are immunized well in advance of exposure. Anthim represents a 'just in time anthrax therapeutic,' that in relevant models has demonstrated complete protection against an anthrax spore challenge with a single prophylactic dose, and has shown significant protection when administered up to two days after a lethal spore challenge,
'/>"/>

SOURCE Elusys Therapeutics, Inc.
Copyright©2007 PR Newswire.
All rights reserved

0

GOOD

Page: 1 2

Related medicine technology :

1. Pelosi: Bush Veto of Stem Cell Bill Says No to the Hopes of Million of Families Across America
2. Trichomoniasis: Most Common Curable STD in U.S. Affects 7.4 Million Annually
3. Antisoma Announces Further Data From ASA404 Ovarian Cancer Trial
4. Molecular Target of Bradmers Neuradiab Further Validated by Independent Findings
5. Phase III Clinical Trial with 4-Month Long-Acting Formulation of Triptorelin: Ipsen Decides Not to Perform Further Administration
6. Further Statistical Analysis of the Recent Phase III trial on Lead Product M6G Shows Additional Benefits
7. New Data on Market-Leading Velcade (Bortezomib) for Injection Further Strengthen Role in Previously Treated Multiple Myeloma
8. Liponex Inc. Reports Further Analysis of CRD5 Phase I/II Clinical Trial Data
9. MIV Therapeutics Announces Pivotal Test Results Further Validating Company Stent Coatings Meet Critical FDA Fatigue Guidelines
10. Lexicon Develops Antibodies That Lower Triglycerides and Cholesterol as Potential New Therapy for Heart Disease
11. Positive Clinical Results for DG041 Lead Product Development Highlights at deCODE R&D Event
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:6/19/2013)... -- Ellen MacArthur Foundation meddelade i ... kommer att vara en partner för att hjälpa ... Efter stiftelsens framgångsrika partnerskap med Renault, BT/Cisco ... att ansluta sig som partner för att få ... verksamhet och stödja stiftelsens arbete inom utbildning. ...
(Date:6/19/2013)... , June 19, 2013 The Physician-Patient Alliance ... alarm fatigue. The need to urgently address this ... its Sentinel Event Alert #50 , "Medical device alarm safety ... database, between January 2008 and June 2012, there were 98 ... resulted in death (82%) , 13 resulted in permanent ...
(Date:6/19/2013)...   BioCision , a leader in advanced ... many areas of medical and scientific research, announced ... U.S. Patent Office that apply to two of ... handling to ensure the consistency of test conditions ... Patent number 8,388,912 covers CoolSink® ...
Breaking Medicine Technology:Ellen MacArthur Foundation presenterar Philips som global partner vid det konstituerande internationella toppmötet om cirkulär ekonomi 2Ellen MacArthur Foundation presenterar Philips som global partner vid det konstituerande internationella toppmötet om cirkulär ekonomi 3Three Lessons Learned to Reduce Alarm Fatigue and Improve Alarm Management and Patient Safety in Hospitals 2Three Lessons Learned to Reduce Alarm Fatigue and Improve Alarm Management and Patient Safety in Hospitals 3BioCision Announces Two New U.S. Patents for Thermo-Conductive Products that Standardize Sample Handling in Laboratory Research 2
... Inc. (Nasdaq: KERX ) today announced that ... from previous clinical trials of Zerenex™ (ferric citrate) were ... the American Society of Nephrology (ASN) Kidney Week 2011 ... ferric iron-based drug candidate, is currently in Phase 3 ...
... and WASHINGTON, Nov. 14, 2011 Nektar Therapeutics (NASDAQ: ... data for NKTR-192, a novel mu-opioid agonist, was presented ... Neuroscience being held November 12-16, 2011 in Washington, DC. ... for the treatment of acute pain.  It is designed ...
Cached Medicine Technology:Keryx Biopharmaceuticals Announces Highlights from Zerenex™ (ferric citrate) Poster Presentations at American Society of Nephrology Kidney Week 2011 Annual Meeting 2Keryx Biopharmaceuticals Announces Highlights from Zerenex™ (ferric citrate) Poster Presentations at American Society of Nephrology Kidney Week 2011 Annual Meeting 3Keryx Biopharmaceuticals Announces Highlights from Zerenex™ (ferric citrate) Poster Presentations at American Society of Nephrology Kidney Week 2011 Annual Meeting 4Positive Data for Nektar's New Mu-Opioid Analgesic Molecule to Treat Acute Pain Highlighted at Neuroscience 2011 2Positive Data for Nektar's New Mu-Opioid Analgesic Molecule to Treat Acute Pain Highlighted at Neuroscience 2011 3Positive Data for Nektar's New Mu-Opioid Analgesic Molecule to Treat Acute Pain Highlighted at Neuroscience 2011 4Positive Data for Nektar's New Mu-Opioid Analgesic Molecule to Treat Acute Pain Highlighted at Neuroscience 2011 5Positive Data for Nektar's New Mu-Opioid Analgesic Molecule to Treat Acute Pain Highlighted at Neuroscience 2011 6
(Date:6/19/2013)... new understanding of the genetic process that can lead ... dangerous lesions for some women, and also raises a ... certain cases suggesting they could actually trigger the ... provides a clearer picture of the chromosomal and genetic ... leads to chronic infection and, in less than 1 ...
(Date:6/19/2013)... study reveals significant disparities between minority and white ... treatment programs. Moreover, these disparities vary widely from ... that for most states there,s something amiss," says ... biostatistics. "There are strong racial and ethnic disparities ... abuse treatment programs successfully, and those disparities are ...
(Date:6/19/2013)... In early April, senior leaders from medical, law enforcement, ... discuss one question: how can first responders improve survival ... preliminary results of this discussion are now available in ... Consensus ," a concept paper published in the June ... and Acute Care Surgery , official publication of ...
(Date:6/19/2013)... ROCHESTER, Minn. -- Nearly 70 percent of ... and more than half take two, Mayo Clinic ... most commonly prescribed, their study found. Twenty percent ... medications, according to the findings, published online in ... MULTIMEDIA ALERT: For audio and video of Dr. ...
(Date:6/19/2013)... 2013 Effective Environmental Services and Clifford Woods, ... These online links are devoted to a range of organic ... Odor Control Mold Magician and others. , Green products are ... in the water as well as living plants. They contain ... can accumulate at the bottom of a pond and render ...
Breaking Medicine News(10 mins):Health News:Genetics of cervical cancer raise concern about antiviral therapy in some cases 2Health News:States vary widely on success rates for minorities in drug treatment programs 2Health News:States vary widely on success rates for minorities in drug treatment programs 3Health News:Hartford consensus aims to improve survival after mass shootings 2Health News:Nearly 7 in 10 Americans are on prescription drugs, Mayo Clinic study finds 2Health News:Effective Environmental Services Launch New Websites to Serve Customers 2
... earthquake devastation are susceptible to psychological problems, drug use, ... has revealed. // ,The report ... Human rights violation and are displaced by coercion. Relief ... and economic opportunities. ,The earthquake also ...
... into analysis of the nation's well being has revealed Scotland ... neighborhood. // Scotland infact deserves the credit of harboring 22 ... were found to be overweight, indulge more on tobacco and ... They were also less likely to involve themselves in sports ...
... In line with the detection of positive bird flu infection ... announced that any tenant (under the public rental system) in ... be subjected to legal action, characterized by a deduction of ... breach the new law would be required to pay a ...
... ill patients at Wellington Hospital’s troubled ward, health officials ... community acute house // in the suburban area. One ... other similar houses would be opened shortly. ... variety of mental health conditions such as depression. Although ...
... works like Magic- an instant stress buster, pain reliever, sleep-inducer, ... the heart// - No marks for guessing! Intimate sex with ... those nagging hiccups! ,The NHS helpline says "Forget ... key for healthy living is, in fact, good bout of ...
... out, the government of Nepal paid compensation of Nepali Rs. 150,000 ... shot dead in Kathmandu valley Monday during a shutdown called by ... ,The government also paid around Nepali Rs.150,000 to the family ... the polls. ,However, when one looks at the contrast ...
Cached Medicine News:Health News:Scotland Ranked As Sickest Area Of UK: Survey 2
... Care Manager is an electronic ... and data management of wounds ... was developed using industry expert ... with the most current assessment ...
... 3000 is a computerized medical ... 3000 encompasses a wide array ... criteria sets and decision tree ... clinicians, medical educators, nurses and ...
... is the handheld version ... a drug interaction analyzer ... and generic drugs. iFacts™ ... refer to accurate and ...
... for 2005, this practical handbook is ... of cancer chemotherapy. The book provides ... of over 100 drugs both on ... cancer treatment. This new edition includes ...
Medicine Products: